Overview

Surveillance Study of NovoRapid® for New Drug Re-examination

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Aspart